(2026). Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: Preliminary evidence from a pilot experience. EJNMMI Research.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Outcome and Safety of Single-dose Docetaxel–augmented Targeted Radionuclide Therapy Using [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Treatment-refractory MCRPC: Preliminary Evidence from a Pilot Experience."
EJNMMI Research 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Outcome and Safety of Single-dose Docetaxel–augmented Targeted Radionuclide Therapy Using [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Treatment-refractory MCRPC: Preliminary Evidence from a Pilot Experience."
EJNMMI Research, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.